ARCUTIS BIOTHERAPEUTICS INC (ARQT) — insider trading
Health Care · NASDAQ
ARCUTIS BIOTHERAPEUTICS INC (ARQT) has 26 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 26 (latest 2026-06-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Welgus Howard G. | Director | Open-market sale | 635 | $25.67 | $16.3K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 2,255 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 1,019 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 822 | $0.00 | $0 | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Open-market sale | 4,096 | $24.41 | $100.0K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion | 2,255 | $8.63 | $19.5K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion | 1,019 | $7.51 | $7.7K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion | 822 | $6.52 | $5.4K | Form 4 |
| 2026-06-15 | LIN SUE-JEAN | Director | Open-market sale | 4,946 | $24.38 | $120.6K | Form 4 |
| 2026-06-05 | Krishnamohan Neha | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Krishnamohan Neha | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Gilbert Halley E | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Gilbert Halley E | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Munshi Amit | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Munshi Amit | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Curran Terrie | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Curran Terrie | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Leonard Keith R | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Leonard Keith R | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Welgus Howard G. | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Welgus Howard G. | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-06-05 | LIN SUE-JEAN | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | LIN SUE-JEAN | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Heron Patrick J | Director | Grant / award / vesting (derivative) | 16,667 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Heron Patrick J | Director | Grant / award / vesting | 5,778 | $0.00 | $0 | Form 4 |
| 2026-05-11 | Vairavan Latha | Officer (SVP Chief Financial Officer) | Open-market sale | 435 | $21.05 | $9.2K | Form 4 |
Ask the chat about ARQT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARCUTIS BIOTHERAPEUTICS INC (ARQT).
Last updated 2026-06-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.